Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I
NCT ID: NCT05884008
Last Updated: 2024-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2023-05-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III
NCT06793774
Quantitative Analysis of Functional CT Imaging of Coronary Atherosclerosis
NCT04986410
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV
NCT06793787
CHART Study of Coronary CT Angiography in Coronary Artery Disease
NCT05380622
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
NCT06748261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received coronary CT angiography 3 months to 5 years prior to acute coronary myocardial infarction. CCTA identified coronary atherosclerotic plaques with diameter stenosis ≥ 10%
Exclusion Criteria
* Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
* Prior history of myocardial infarction before the recent event
* Severe liver or renal insufficiency
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
RUIYAN ZHANG
Director of Cardiology Department, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ruiyan Zhang, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Lin Lu, M.D., Ph.D.
Role: STUDY_CHAIR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cangzhou Center Hospital
Cangzhou, Hebei, China
First affiliated hospital of Harbin Medical University
Harbin, Heilongjiang, China
First affiliated hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Techonology
Wuhan, Hubei, China
First Hospital of Nanjing
Nanjing, Jiangsu, China
First affiliated hospital of Dalian Medical College
Dalian, Liaoning, China
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Xinhua Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Run Guo, M.D.
Role: primary
Lei Liu, M.D.
Role: primary
Yingying Zheng, M.D.
Role: primary
Tian Xie, M.D.
Role: primary
Fei Ye, M.D.
Role: primary
Xiaolei Yang, M.D.
Role: primary
Geng Wang, M.D.
Role: primary
Yachen Zhang, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022YFC2533502-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.